However, its important to know what isnt typical
doi:10.1056/NEJMoa1812792 Yokoyama M, Origasa H, Matsuzaki M, et al
Those were not head-to-head obesity trials, so they are useful for direction, not as a guarantee for any one person
Prevention candidates: Given the observational data suggesting reduced autoimmune disease risk in GLP-1 users, some practitioners are considering microdosing for patients with strong family histories or early biomarker evidence of autoimmune activation before clinical disease manifests
Track your sites: Note where you injected last so you can avoid returning to the same spot too soon
If you develop symptoms suggestive of gallbladder problems while on a GLP-1, or at any time for that matter, you have two incredibly important specialists in your corner: The takeaway